These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31156712)

  • 1. Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Front Genet; 2019; 10():461. PubMed ID: 31156712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):496-504. PubMed ID: 32710539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Flisar D; Kojović M; Gregorič Kramberger M; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    Front Pharmacol; 2019; 10():8. PubMed ID: 30745869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
    Redenšek S; Flisar D; Kojović M; Kramberger MG; Georgiev D; Pirtošek Z; Trošt M; Dolžan V
    J Neuroinflammation; 2019 Feb; 16(1):50. PubMed ID: 30813952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
    Soraya GV; Ulhaq ZS; Shodry S; A'raaf Sirojan Kusuma M; Herawangsa S; Sativa MO; Gustaf A; Faridwazdi DAN; Florentia SW; Raisa N; Bintang AK; Akbar M
    Neurol Sci; 2022 Jun; 43(6):3649-3670. PubMed ID: 35079903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Catechol-O-Methyltransferase Gene Polymorphisms and Haplotypes in the Levodopa-Induced Adverse Events in Subjects with Parkinson's Disease.
    Fatima TS; Fathima ST; Kandadai RM; Borgohain R; Sreenu B; Kutala VK
    Indian J Clin Biochem; 2023 Apr; 38(2):262-274. PubMed ID: 37025429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
    Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.
    Rieck M; Schumacher-Schuh AF; Altmann V; Callegari-Jacques SM; Rieder CRM; Hutz MH
    Pharmacogenomics J; 2018 Jan; 18(1):196-200. PubMed ID: 27779245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.
    Santos-Lobato BL; Schumacher-Schuh AF; Rieder CRM; Hutz MH; Borges V; Ferraz HB; Mata IF; Zabetian CP; Tumas V
    Arq Neuropsiquiatr; 2020 Apr; 78(4):206-216. PubMed ID: 32294749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictive factors of subthalamic stimulation in Parkinson's disease.
    Welter ML; Houeto JL; Tezenas du Montcel S; Mesnage V; Bonnet AM; Pillon B; Arnulf I; Pidoux B; Dormont D; Cornu P; Agid Y
    Brain; 2002 Mar; 125(Pt 3):575-83. PubMed ID: 11872614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.